Direct Medical Costs Associated with the Extrahepatic Manifestations of Hepatitis C Virus Infection in France

Patrice Cacoub¹, Mathieu vautier², Anne-Claire Desbois³, David Saadoun⁴ and Zobair Younossi⁵, ¹Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ²Médecine Interne 1, Hôpital Pitié-Salpêtrière, Paris, France, ³Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, ⁴Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ⁵Medicine, Inova Fairfax Hospital, Falls Church, Falls Church, VT

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: cost containment and vasculitis, Hepatitis C

Session Information

Date: Sunday, November 5, 2017

Title: Infection-related Rheumatic Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The economic impact of the extrahepatic manifestations (EHM) of hepatitis C virus (HCV) infection remains unknown for France. To estimate the prevalence of HCV-EHM and the direct medical costs associated with HCV-EHM in France.

Methods: Estimates of thirteen EHM prevalence were obtained (i) from a retrospective data analysis of HCV-infected patients in specialized center in France, and the baseline prevalence in the general French population and (ii) from an international systematic review and meta-analysis. Per-patient-per-year (PPPY) inpatient, outpatient and medication costs to treat EHM in France were obtained from the literature, national databases, or expert opinion. The impact of achieving SVR after antiviral therapy was applied to the French healthcare costs.

Results: Using approach (i), increased EHM prevalence rates in HCV patients compared to the general population were observed for most EHM, including cryoglobulinemia vasculitis (51.5% vs. 1.5%), rheumatoid-like arthritis (47.8% vs. 0.1%) and lymphoma (14.2% vs. 0.24%). The mean PPPY cost of EHM in the French tertiary center was 3,296 € [95% CI 1,829; 5,540]. In France, HCV-EHM amounted to a total cost of 215 million (M) € per year [144; 299]. Using approach (ii), the mean PPPY cost of EHM in France was estimated to be 1,117 €. The estimated total cost reduction in France associated with SVR was 13.9 M€ for diabetes, 8.6 M€ for cryoglobulinemia vasculitis, 6.7 M€ for myocardial infarction, 2.4 M€ for end-stage renal disease, and 1.4 M€ for stroke.

Conclusion: Extrahepatic manifestations of HCV infection substantially add to the overall economic burden of HCV infection in France. Sustained virological response after antiviral therapy is expected to significantly reduce the total costs of managing HCV-EHM in France.

Disclosure: P. Cacoub, None; M. vautier, None; A. C. Desbois, None; D. Saadoun, None; Z. Younossi, None.

To cite this abstract in AMA style:

Cacoub P, vautier M, Desbois AC, Saadoun D, Younossi Z. Direct Medical Costs Associated with the Extrahepatic Manifestations of Hepatitis C Virus Infection in France [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/direct-medical-costs-associated-with-the-extrahepatic-manifestations-of-hepatitis-c-virus-infection-in-france/. Accessed .

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/direct-medical-costs-associated-with-the-extrahepatic-manifestations-of-hepatitis-c-virus-infection-in-france/